The focus of our future studies will thus be elucidation of the molecular mechanisms mediating this effect as well as determination of whether the observed obesity-induced inhibition of ERβ levels affects breast cancer progression in vivo. The gene discussed is ESR2; the disease is obesity due to melanocortin 4 receptor deficiency.